Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the
introduction of interferon‐α monotherapy in 1992 to the approval of telaprevir‐and …

Recent genome-wide association studies (GWAS) have identified genetic variations near
the IL28B gene which are strongly associated with spontaneous and treatment-induced …

Recent data have clearly shown that a sustained virologic response can be achieved in
different HCV infected patient populations with various interferon-free treatment regimens …

Entecavir is a potent nucleoside inhibitor of the hepatitis B virus (HBV) polymerase with a
high antiviral efficacy and a high genetic barrier to viral resistance. After approval in 2006 …

Vitamin D is an important immune modulator that plays an emerging role in inflammatory
and metabolic liver diseases, including infection with hepatitis C virus (HCV). In contrast, the …

Objective: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world
HCC cohort, including patients with impaired liver function and prior systemic therapy …

Abstract Background & Aims Acute‐on‐chronic liver failure (ACLF) is characterized by an
acute deterioration of liver function in patients with cirrhosis in combination with recently …

Vaccination against SARS-CoV-2 infection is currently approved and shows favorable
outcomes, but little known about antibody responses in solid organ transplant recipients …

Background & Aims Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen.
In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most …

Background & Aims Based on positive results from small single center studies, granulocyte-
colony stimulating factor (G-CSF) is being widely used for the treatment of patients with …